Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-26

Clinical Trial Update: DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

View source ↗

Summary

Retrospective study update of DEXYCU 9% intraocular suspension in cataract patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dexycu (dexamethasone intraocular suspension)

Snippet

Sponsor: EyePoint Pharmaceuticals, Inc. | Conditions: Cataract | Status: COMPLETED | Results posted: 2021-05-26